amplia

The US Food and Drug Administration (FDA) has granted approval for Irish firm Medtronic’s magnetic resonance imaging (MRI) conditional cardiac resynchronisation therapy defibrillators (CRT-Ds) to treat heart failure.

The approved CRT-Ds, Amplia MRI Quad CRT-D SureScan and Compia MRI Quad CRT-D SureScan systems are designed to perform MRI scans on any part of the body without positioning restrictions.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

According to the company, both CRT-D systems will be commercially available in the coming months and they will help patients treat their heart failure, as well as and reduce their risk of sudden cardiac arrest.

Medtronic cardiac rhythm and heart failure division medical director David Steinhaus said: "With FDA approval of Amplia MRI and Compia MRI, Medtronic continues to lead the market in MR-conditional implantable cardiac devices, bringing greater access to patients that need this vital diagnostic test to identify other potential life-threatening diseases.

"Medtronic is committed to continuing to develop innovative technologies that offer physicians a wide range of technology options to help them improve outcomes for heart failure patients."

"Both devices feature quadripolar technology and provide multiple options to physicians for treatment of heart failure."

Both devices feature quadripolar technology and provide multiple options to physicians for treatment of heart failure by optimising CRT delivery.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Amplia MRI device features the AdaptivCRT algorithm, which is said to reduce patient’s odds of a heart failure hospital readmission by 59% compared to echo-optimised CRT.

The devices can also be paired with Attain Perfoma MRI SureScan Quadripolar leads, including Dual Cant MRI SureScan Model 4298, Straight MRI SureScan Model 4398 and S MRI SureScan Model 4598.

With 16 pacing configurations and shorter spacing between the two centre electrodes, these quadripolar leads were shown to reduce the incidence of phrenic nerve stimulation (PNS).

The company received FDA approval for MR-conditional pacemakers in 2011 and implantable cardioverter defibrillators (ICDs) in 2015.

Image: Amplia MRI cardiac resynchronisation therapy-defibrillator. Photo: courtesy of Medtronic plc.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact